

9 May 2017

PureTech Health plc

Results of Annual General Meeting

The Annual General Meeting of [PureTech Health plc](#) (“PureTech”, LSE: PRTC) plc was held at 17.00 BST on Monday 8 May 2017. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll.

The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.

Resolutions	For	%	Against	%	Withheld	Total votes cast
001. To approve the Company's Annual Report and Accounts for year end 31 December 2016	179,399,131	100.00	0	0.00	0	179,399,131
002. To approve the Directors' Remuneration Report	174,260,790	97.14	5,138,341	2.86	0	179,399,131
003. To elect Mr. Joichi Ito as a Director	179,399,131	100.00	0	0.00	0	179,399,131
004. To elect Dr. Raju Kucherlapati as a Director	179,399,131	100.00	0	0.00	0	179,399,131
005. To elect Dr. John LaMattina as a director	179,399,131	100.00	0	0.00	0	179,399,131
006. To elect Dame Marjorie Scardino as a director	179,399,131	100.00	0	0.00	0	179,399,131
007. To elect Mr. Christopher Viehbacher as a director	179,399,131	100.00	0	0.00	0	179,399,131
008. To elect Dr. Robert Langer as a director	175,561,073	97.95	3,665,851	2.05	172,207	179,226,924
009. To elect Dr. Bennett Shapiro as a director	173,797,010	96.97	5,429,914	3.03	172,207	179,226,924
010. To elect Ms. Daphne Zohar as a director	179,399,131	100.00	0	0.00	0	179,399,131
011. To elect Mr. Stephen Muniz as a director	179,399,131	100.00	0	0.00	0	179,399,131
012. To reappoint KPMG LLP as Auditors of the Company	179,399,131	100.00	0	0.00	0	179,399,131

013. To authorise the Board of Directors to determine the Auditors' remuneration	179,399,131	100.00	0	0.00	0	179,399,131
014. To authorise the allotment of shares	173,622,534	96.78	5,776,597	3.22	0	179,399,131
015. To dis-apply pre-emption rights	179,109,365	99.84	289,766	0.16	0	179,399,131
016. To dis-apply pre-emption rights in limited circumstances	173,622,534	96.78	5,776,597	3.22	0	179,399,131
017. To authorise market purchase of own shares	179,109,365	99.84	289,766	0.16	0	179,399,131
018. To authorise general meetings to be called on not less than 14 clear days' notice	178,716,991	99.62	682,140	0.38	0	179,399,131

Due to its shareholding in the Company, Invesco Asset Management Limited is deemed to be a controlling shareholder as defined in the Financial Conduct Authority's Listing Rules. Accordingly, each resolution to elect an independent director (resolutions 4, 5, 6 and 7) has under Listing Rule 9.2.2E been approved by a majority of the votes cast by:

- the shareholders of the Company as a whole; and
- the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution excluding the controlling shareholder as shown below.

Resolutions	For	%	Against	%	Withheld	Total votes cast
004. To elect Dr. Raju Kucherlapati as a Director	103,602,134	100	0	0	0	103,602,134
005. To elect Dr. John LaMattina as a director	103,602,134	100	0	0	0	103,602,134
006. To elect Dame Marjorie Scardino as a director	103,602,134	100	0	0	0	103,602,134
007. To elect Mr. Christopher Viehbacher as a director	103,602,134	100	0	0	0	103,602,134

Notes:

A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

As at 8 May 2017, the number of issued shares in the Company was 237,387,951 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company's website www.puretechhealth.com and on the National Storage Mechanism.

In accordance with Listing Rule 9.6.2, a copy of the resolutions, other than those concerning ordinary business has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines that modulate the adaptive human systems. PureTech's therapies target the dysfunctions in the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. The Company is advancing a rich pipeline that includes multiple human proof-of-concept studies and pivotal or registration studies expected to read out over the next 12-18 months. PureTech Health's growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts, who along with PureTech's experienced team and a stellar Board identify, analyse and advance very selectively the opportunities the Company believes hold the most promise for patients. This experienced and engaged team places PureTech Health at the forefront of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter [@puretechh](https://twitter.com/puretechh).

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

PureTech Health

Allison Mead
+1 617 651 3156
amead@puretechhealth.com

FTI Consulting

Ben Atwell, Matthew Cole, Rob Winder
+44 (0) 20 3727 1000